E.U. Starts In-Depth Investigation Into Google/DoubleClick Deal
Client Alert | less than 1 min read | 11.15.07
European Union regulators continue their investigation of the potential impact on competition of Google's proposal to buy DoubleClick by opening a "second phase," which will extend the investigation for approximately four months. The deal is already under scrutiny in the U.S. after competitors such as Yahoo Inc. and Microsoft Corp. expressed concerns that the combination would hurt competition in the $40.6 billion global online-advertising market. In the E.U., publishers have also urged regulators to look at how Google's bid for DoubleClick may reduce advertising choices for media companies.
Insights
Client Alert | 2 min read | 09.18.25
On September 9, 2025, the U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration (HHS) issued a news release announcing an “aggressive[]” “crackdown” on direct-to-consumer pharmaceutical advertising. This release came on the heels of a Presidential Memorandum President Trump issued the same day directing HHS to “ensure transparency and accuracy in direct-to-consumer prescription drug advertisements,” and the FDA to “take action to enforce legal requirements that advertisements for prescription drugs be truthful and not misleading.”
Client Alert | 3 min read | 09.17.25
Client Alert | 4 min read | 09.17.25
Client Alert | 5 min read | 09.16.25
Bucking the Odds: Why Technology Companies Should Embrace Software Patents Today
